Published in final edited form as:

Biochem Biophys Res Commun. 2015 June 5; 461(3): 533–536. doi:10.1016/j.bbrc.2015.04.063.

Role of PTEN in TNF Induced Insulin Resistance

David A Bulger^{1,2,3,4}, Jermaine Conley², Spencer H Conner^{1,2}, Gipsy Majumdar^{1,2}, and Solomon S Solomon^{1,2}

¹Departments of Medicine and Pharmacology, University of Tennessee Health Science Center, Memphis, TN 38163, USA

²Medicine and Research Services, Veterans Association Medical Center, Memphis, TN 38104, USA

³Wellcome Trust Medical Research Council Institute of Metabolic Science, Cambridge, CB2 0QQ, UK

⁴National Institute of Diabetes & Digestive & Kidney Disease, National Institutes of Health, Bethesda, MD 20892, USA

Abstract

Aims/hypothesis—PTEN may play a reversible role in TNF α induced insulin resistance, which has been linked to obesity-associated insulin resistance (IR).

Methods—Western blots for PTEN and p-Akt were performed on H-411E liver cells incubated with insulin, TNF α , and in selected experiments VO-OHpic vanadium complex in the presence and absence of PTEN siRNA. Total PTEN was compared to β -actin loading control and p-Akt was compared to total Akt.

Results—Western blot and Real Time RT-PCR experiments showed increased PTEN after TNF α treatment ($p = 0.04$); slightly decreased PTEN after insulin treatment; and slightly increased PTEN after insulin + TNF α treatment. PTEN siRNA markedly inhibited the TNF α -induced increase in PTEN ($p < 0.01$) without significantly changing the p-Akt levels. The vanadium complex, exhibiting insulin-like effects, also significantly prevented the TNF α -induced increase in PTEN. Combining insulin and VO-OHpic was additive, providing both proof of concept and insight into mechanism.

Discussion—The PTEN increase due to TNF α treatment was reversible by both PTEN siRNA knockdown and VO-OHpic treatment. Thus, PTEN is identified as a potential new therapeutic target for reducing IR in Type 2 DM.

© 2015 Published by Elsevier Inc.

Corresponding author and person to whom reprint requests should be addressed: Solomon S. Solomon, MD, Medicine and Research Services, VA Medical Center, B120/Research SVC(151), 1030 Jefferson Ave, Memphis, TN 38104, ssolomon@uthsc.edu.

Contribution statement

SS conceived the study and secured its support. DB drafted the article. SS, GM, and DB designed the study. GM, DB, JC, and SC obtained the data. SS, GM, DB, JC, and SC interpreted the data. All authors reviewed the article and approved the final draft.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Key terms

diabetes; insulin resistance; hepatocytes; obesity; adipocyte

Introduction

In the last 20 years, diabetes has sharply increased in all age, sex, and racial/ethnic groups and is only now beginning to level off according to available Center for Disease Control (CDC) data^{1,2}. Most type 2 diabetics are obese and adipose tissue TNF α levels and IR increase in obese animals and man³⁻⁶. TNF α -null mice show reduced insulin levels reflecting increased insulin sensitivity and reduced fat pad weight despite a high fat diet. In experiments using human tissue(s) in culture, treatment with TNF α produced IR in adipocytes and hepatocytes, but not in primary skeletal myocytes⁶⁻¹². As an extension of this, our group has previously shown that patients with DM2 being treated with anti-TNF α medications (etanercept and infliximab) demonstrated a reduction in fasting blood glucose (FBG), HbA_{1c}, and fasting plasma triglyceride (TG) values¹³.

While others have shown that increased TNF α leads to IR, it is still unknown how this change occurs. Some proposed mechanisms include decreased INSR, increased lipolysis, decreased insulin-responsive glucose transporter 4 (GLUT4), decreased peroxisome proliferator-activator receptor gamma (PPARG), and changes in IRS-1 phosphorylation. TNF α phosphorylates the serines in IRS-1 essential for insulin signaling, leading to IR⁶. Our group has previously identified yet another possible mechanism, increased PTEN expression. Using proteomic and genomic assays, our group found two networks that were reciprocally changed by insulin and TNF α : insulin signaling and apoptosis¹⁴. Additionally, these two networks converge on a single protein, phosphatase and tensin homolog deleted on chromosome 10 (PTEN). These previous experiments strongly suggested that an increase in PTEN levels play a vital and opposing role in each of these major actions of TNF α : termination of insulin signaling and regulation of apoptosis^{7,14}.

In the current study, we analyzed the effects of various treatments including insulin, TNF α , 3-hydroxypicolinate vanadium (IV) complex (VO-OHpic), and siRNA PTEN on the levels of PTEN and p-Akt. While most phosphatase inhibitors have very general and non-specific inhibitory effects, VO-OHpic is currently the most specific chemical inhibitor of PTEN due to its non-competitive mechanism of inhibition^{15,16}. This experiment used siRNA targeting PTEN mRNA to see the effects of a specific knockdown of PTEN on insulin signaling and IR. Our results show a central role for PTEN in TNF α induced IR in H-411E rat hepatoma cells with this form of IR to some extent mimicking IR as seen in obese human DM2.

Materials and Methods

Cell Culture

Minimally deviant hepatoma cells derived from rat liver (H-411E cells; ATCC, Manassas, Virginia) were cultured in 10 mL Eagles minimal essential medium (MEM) supplemented with 1% glutamine, 10% calf serum, and 5% fetal calf serum (FCS) at 37 C under a

humidified 5% CO₂/95% O₂ atmosphere using 100-mm dishes. After cells had grown from $\sim 3.0 \times 10^6$ cells/plate to 80% confluency with $\sim 15 \times 10^6$ cells/plate, medium was aspirated and cells were rinsed with serum free medium (SFM) before overnight incubation. Next, medium was replaced with 10 mL of fresh SFM 4 hours before protein isolation. TNF α treatment involved 10 mL of SFM containing TNF α (1 mg/l) from R&D Systems (Minneapolis, Minnesota) in SFM before and after overnight incubation. After overnight incubation, insulin treatment involved 500 μ L of insulin (10 000 mU/l) (Sigma-Aldrich, St Louis, Missouri) and VO-OHpic treatment involved 10 mmol/l VO-OHpic (Sigma-Aldrich, St Louis, Missouri).

Knock down of PTEN Expression with siRNA

After overnight culture as above, H411E cells were incubated with 2mM siRNA in antibiotic free complete culture media. Dharmafect reagent was used for siRNA transfection (Dharmacon Inc., Lafayette, CO). After 12 h, the transfected cells were treated as above.

Protein Isolation and Western Blotting

Cells were washed with 5 mL PBS (pH 7.4), aspirated, and scraped with RIPA buffer (0.8 ml/plate) over ice, lysed (21-gauge needle), and left on ice with 10 μ l phenylmethylsulfonyl fluoride (PMSF) (100 mg/ml) for 45 minutes before centrifuging at 10,000g at 4 C for 10 min. Supernatant protein was separated by SDS-PAGE, electroblotted onto polyvinylidene fluoride membrane (PVDF), incubated with primary antibodies followed by horseradish peroxidase-conjugated anti-rabbit IgG antibodies according to manufacturer's instructions (Santa Cruz), visualized with ECL Prime kit (Amersham-Pharmacia Biotech, Piscataway, New Jersey), and quantified using Image J¹⁷.

RNA Isolation

Total RNA from control and treated cells was extracted with TRIzol according to the manufacturers protocol (Invitrogen Life Technologies). cDNA synthesis performed according to manufacturer's instructions using 1 μ g sample RNA (Superscript III, Invitrogen).

Real-Time Quantitative RT-PCR

The primers for human PTEN were Forward: 5-CAA GAT GAT GTT TGA AAC TAT TCC AAT G-3 and Reverse: 5-CCT TTA GCT GGC AGA CCA CAA3. The mRNA levels were acquired from the value of the threshold cycle (Ct) of PTEN. β -Actin mRNA levels were used as a control.

Results

TNF α increases PTEN protein and mRNA levels in H-411E liver cells

We measured PTEN protein levels in H411E cells treated with TNF α in the presence and absence of insulin (Figure 1A). These results were confirmed by real time quantitative PCR (Figure 1B). Both studies are in complete agreement. Compared to control, insulin and

insulin + TNF α did not change the expression of PTEN significantly. However, TNF α alone significantly increased PTEN protein and mRNA expression compared to control ($p < 0.05$).

Insulin increases p-Akt protein levels in H-411E liver cells

TNF α did not significantly change p-Akt levels compared to control; insulin + TNF α treatment did not significantly change p-Akt levels compared to insulin alone; however, insulin did significantly increase p-Akt compared to control with ($p = 0.012$) and without TNF α ($p = 0.011$) (Figure 2). The absence of an inhibitory effect of TNF α on p-Akt in the combination experiment demonstrates the greater potency of insulin over TNF α in these experiments.

Knockdown of PTEN prevented TNF α induced increase in PTEN in H-411E liver cells

PTEN siRNA knockdown of PTEN by siRNA alone prevented the TNF α -induced increase in PTEN ($p < 0.01$) (Figure 3A). The p-Akt and T-Akt analysis (Figure 3B) confirmed that insulin increased p-Akt levels and revealed that neither TNF α nor siRNA knockdown of PTEN significantly changed p-Akt compared to the negative siRNA control.

VO-OHPic prevented the TNF α induced increase in PTEN in H-411E liver cells

VO-OHPic alone did not significantly change PTEN compared to control. However, VO-OHPic prevented the TNF α induced increase in PTEN with and without additional insulin treatment ($p < 0.05$) (Figure 4).

Discussion

This study has confirmed that TNF α increases PTEN and insulin increases p-Akt in H-411E liver cells at both the mRNA and protein levels (Figure 1). This TNF α -induced increase in PTEN was prevented by both VO-OHPic and siRNA knockdown of PTEN. Through non-competitive inhibition, VO-OHPic achieves more specific inhibition of PTEN than the general phosphatase inhibitors¹⁵. In addition to the *in vitro* specificity for PTEN previously reported, herein we show that part of the *in vivo* mechanism of VO-OHPic involves decreasing the amount of PTEN protein. This effect still supports the previous finding that VO-OHPic increased p-Akt signaling in NIH 3T3, L1 fibroblasts, and UmUc-3 epithelial cells¹⁶.

Two recent papers have highlighted the importance of PTEN in obesity and diabetes^{18,19}. Both PTEN haploinsufficiency patients and hibernating grizzly bears are overweight with healthy fat and show little evidence of insulin resistance. Before winter hibernation, grizzly bears store up to 60 pounds of fat. Despite being overweight, the bears are sensitive to insulin's antilipolytic effect promoting storage of fat as triglyceride. During hibernation, bears become insulin resistant, and epinephrine and glucagon break down fat for energy utilization. Within a few days of coming out of hibernation, the bears' metabolism reverts back to pre-hibernation. These changes in metabolism throughout the hibernation cycle were then shown to be mediated by the PTEN/p-Akt switch. It seems very reasonable that this switch is mediated through a cascade of hormones, which might be targeted by selective

drug therapy. Both of these studies can be linked with the TNF α -induced IR tissue culture model presented here.

TNF α has previously been found to cause insulin resistance (IR) in many cells and is thought to be a key player in obesity-associated insulin resistance in humans⁶. Many mechanisms have previously been proposed for TNF α -induced IR, and our lab has recently found PTEN gene expression to be increased in TNF α treated H-411E rat hepatoma cells in tissue culture¹⁴. Using the same H-411E cell line as before, we have now shown that TNF α causes a significant increase in PTEN mRNA and protein. The increase in PTEN protein might sensitize TNF α 's ability to induce apoptosis through nuclear factor kappa-light-chain-enhancer of activated B cells (NF κ B). These findings identify yet another part of the critical mechanism whereby TNF α induces apoptosis. Thus, PTEN has been identified as a central player in both insulin signaling/resistance and apoptosis. PTEN is then a key therapeutic target for IR in obesity-associated DM2 or metabolic syndrome. It is likely that drugs inhibiting PTEN in insulin-sensitive tissue potentially represent a new approach which would likely be additive in effect to other existing therapies.

Acknowledgments

The authors thank Ms. Eva Bryant, Dr. Syamal Bhattacharya, and Dr. Solomon Solomon for administration of the UTHSC Medical Student Research Program and Mrs. Neha Bhargava, Science Technologist at VAMC, for sharing reagents and insightful questions.

Funding

This research was funded by the NIH Training Grant #T35-DK-07405 and by past Merit Review Grants (VA) to Dr. Solomon.

Abbreviations

VO-OHpic	3-hydroxypicolinate vanadium (IV) complex
CDC	Center for Disease Control
MEM	Eagles minimal essential medium
FBG	fasting blood glucose
TG	fasting plasma triglyceride
IR	insulin resistance
NFκB	nuclear factor kappa-light-chain-enhancer of activated B cells
PPARG	peroxisome proliferator-activator receptor gamma
PMSF	phenylmethylsulfonyl fluoride
PTEN	phosphatase and tensin homolog deleted on chromosome 10
PVDF	polyvinylidene fluoride membrane
SFM	serum free medium

References

1. CDC. Increasing Prevalence of Diagnosed Diabetes — United States and Puerto Rico, 1995–2010. MMWR. 2012; 61(45):918–921. [PubMed: 23151951]
2. Geiss LS, Wang J, Cheng YJ, et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980–2012. Jama. 2014; 312(12):1218–1226. [PubMed: 25247518]
3. Control CfD, Prevention, Control CfD, Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. p. 201
4. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D'Agostino RB. Trends in the Incidence of Type 2 Diabetes Mellitus From the 1970s to the 1990s. Circulation. 2006; 113(25):2914–2918. [PubMed: 16785337]
5. Bloomgarden ZT. American Diabetes Association Annual Meeting, 1999: diabetes and obesity. Diabetes Care. 2000; 23(1):118–124. [PubMed: 10857981]
6. Moller DE. Potential Role of TNF- α in the Pathogenesis of Insulin Resistance and Type 2 Diabetes. Trends in Endocrinology & Metabolism. 2000; 11(6):212–217. [PubMed: 10878750]
7. Solomon SS, Odunusi O, Carrigan D, et al. TNF- α Inhibits Insulin Action in Liver and Adipose Tissue: A Model of Metabolic Syndrome. Horm Metab Res. 2010; 42(EFirst):115–121. [PubMed: 19960405]
8. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444(7121):875–880. [PubMed: 17167476]
9. Hotamisligil G, Shargill N, Spiegelman B. Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. Science. 1993; 259(5091):87–91. [PubMed: 7678183]
10. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012; 119(3):651–665. [PubMed: 22053109]
11. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. The Journal of Clinical Investigation. 1995; 95(5):2111–2119. [PubMed: 7738178]
12. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor- α in human obesity and insulin resistance. The Journal of Clinical Investigation. 1995; 95(5):2409–2415. [PubMed: 7738205]
13. Gupta-Ganguli M, Cox K, Means B, Gerling I, Solomon SS. Does Therapy With Anti-TNF- α Improve Glucose Tolerance and Control in Patients With Type 2 Diabetes? Diabetes Care. 2011; 34(7):e121–121. [PubMed: 21709287]
14. Solomon SS, Buss N, Shull J, et al. Proteome of H-411E (liver) cells exposed to insulin and tumor necrosis factor- α : Analysis of proteins involved in insulin resistance. Journal of Laboratory and Clinical Medicine. 2005; 145(5):275–283. [PubMed: 15902099]
15. Mak LH, Vilar R, Woscholski R. Characterisation of the PTEN inhibitor VO-OHpic. Journal of chemical biology. 2010; 3(4):157–163. [PubMed: 21643420]
16. Rosivatz E, Matthews JG, McDonald NQ, et al. A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS chemical biology. 2006; 1(12):780–790. [PubMed: 17240976]
17. Abràmoff MD, Magalhães PJ, Ram SJ. Image processing with ImageJ. Biophotonics international. 2004; 11(7):36–43.
18. Pal A, Barber TM, Van de Bunt M, et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. The New England journal of medicine. 2012; 367(11):1002–1011. [PubMed: 22970944]
19. Nelson OL, Jansen HT, Galbreath E, et al. Grizzly bears exhibit augmented insulin sensitivity while obese prior to a reversible insulin resistance during hibernation. Cell metabolism. 2014; 20(2):376–382. [PubMed: 25100064]

Highlights

- TNF α treatment induced a significant increase in PTEN in H-411E liver cells
- PTEN siRNA knockdown prevented this effect
- VO-OHpic (vanadium complex) treatment, like insulin, decreased PTEN protein levels
- Thus, PTEN is identified as a potential therapeutic target in DM Type 2

Figure 1.

PTEN expression in H411E cells following insulin and TNF α treatment. A: PTEN protein levels in insulin treated cells in the absence and presence of TNF α . Representative Western blots along with a bar graph quantifying the band densities of the three PTEN blots normalized against β -Actin calculated as percentages of control. Data are expressed as mean $\pm$ SD (n = 3). B: Relative expression of PTEN mRNA in insulin treated cells with and without TNF α . The steady state levels of mRNA encoding PTEN were analyzed by Real Time RT-PCR (n = 1).

Figure 2.

p-Akt protein levels measured in insulin treated H411E cells in the presence and absence of TNF α . Representative Western blots of p-Akt and total Akt (T-Akt) in response to insulin and TNF α are shown. Densitometric quantification of p-Akt expression normalized against T-Akt and calculated as percentages of control. Data are expressed as mean $\pm$ SD (n = 3).

Figure 3.

siRNA knockdown of PTEN significantly prevented TNF α -induced increase in PTEN without affecting p-Akt levels. A: Representative western blot above with bar graph quantifying the PTEN and β -Actin antibody band densities calculated as percentages of control. Data are expressed as mean $\pm$ SD (n = 3). B: Representative western blot above with bar graph quantifying the p-Akt and T-Akt antibody band densities calculated as percentages of control. Data are expressed as mean $\pm$ SD (n = 3). Insulin was added as a positive control.

Figure 4. VO-OHpic significantly prevented $\text{TNF}\alpha$ -induced increase in PTEN with and without insulin treatment. With the representative blot above and the quantified band bar plot below, PTEN levels are compared with β -Actin loading control normalized to control. Data are expressed as mean $\pm$ SD ($n = 3$).